releases Archive — Page 31 of 53

March 26, 2008

Racial Disparities Persist for Colonoscopy Screenings

African-Americans are far more likely to be diagnosed with and to die from colorectal cancer than whites or other minority groups. Despite this increased risk, a new study led by Vanderbilt University Medical Center researchers found that African-Americans are far less likely to undergo colonoscopy screening than whites, even when both groups have a family history of colorectal cancer. The study was published in the March 24 issue of the Archives of Internal Medicine.

March 25, 2008

New Research Projects Growing Nursing Shortage

The United States health care system needs to brace for a severe shortage of nurses, according to findings by Peter Buerhaus, Ph.D., of Vanderbilt University School of Nursing, Douglas Staiger, Ph.D., from Dartmouth University, and David Auerbach, Ph.D., of the Congressional Budget Office.

March 24, 2008

Teen cancer survivor a finalist for exclusive Medal of Honor Society award

Although she\’s just 15, Katlyn Vacanti-Mitchell has already battled leukemia and started her own foundation to help families with sick children at Monroe Carell Jr. Children\’s Hospital at Vanderbilt.

March 19, 2008

Vanderbilt Heart Lebanon Hosts Open House

Vanderbilt Heart Lebanon will host an open house and ribbon cutting ceremony on Wednesday, March 26, at 4 p.m. The clinic, which opened in February, is located at 1420 W. Baddour Pkwy., across the street from University Medical Center.

March 13, 2008

Vanderbilt-Ingram Cancer Center named Blue Distinction Center for Complex and Rare CancersSM

Vanderbilt-Ingram Cancer Center has been selected as a Blue Distinction Center for Complex and Rare CancersSM by Blue Cross Blue Shield Association, in collaboration with BlueCross BlueShield of Tennessee.

By Vanderbilt Health News
March 13, 2008

Vanderbilt-Ingram Researchers Find Clue to Cancer Drug Allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.